Cancer clinical trials in the region Bourgogne-Franche-Comté

204 currently recruiting clinical trials
Region Bourgogne-Franche-Comté

Early Access Liver and bile duct cancer
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Jazz Pharmaceuticals
Early Access Bladder / Urinary Tract / Urethral cancer
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Early Access Bladder / Urinary Tract / Urethral cancer
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Astellas Pharma Développement mondial, Inc.
Early Access Kidney cancer Pancreas cancer
Required histologic types
Clear cell carcinoma
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Localized
Required genetic anomalies
Von Hippel-Lindau syndrome (VHL)
1 recruiting site
Merck Sharp & Dohme LLC
Early Access Lymphoma
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Hoffmann-La Roche
Early Access Lung cancer
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Janssen
Phase 3 Lymphoma #NCT06006117 #2022-501810-77-00
Required histologic types
B cell lymphoma
Required histologic sub types
Marginal zone lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Targeted therapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant
23 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3 Lymphoma #NCT06284122 #2023-505436-35-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required renal function statuses
30-50 ml/min < 30 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Allogeneic stem cell transplant Radiotherapy
37 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3 Stomach and esophageal cancer #NCT06901531 #2024-519773-19-00
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
17 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 3 Multiple myeloma #NCT06918002 #2024-516418-39-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
56 recruiting sites
Intergroupe Francophone du Myélome